These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17532670)

  • 1. Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis.
    Lucioni C; Mazzi S; Rossi C
    Clin Drug Investig; 2005; 25(5):325-36. PubMed ID: 17532670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
    Edwards SJ; Lind T; Lundell L
    Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
    Wahlqvist P; Junghard O; Higgins A; Green J
    Pharmacoeconomics; 2002; 20(4):279-87. PubMed ID: 11950384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
    Wahlqvist P; Junghard O; Higgins A; Green J
    Pharmacoeconomics; 2002; 20(4):267-77. PubMed ID: 11950383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulary management of proton pump inhibitors.
    Byrne MF; Murray FE
    Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
    Yaghoobi M; Padol S; Yuan Y; Hunt RH
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E; Brown RE; Yuen C; Robinson A
    Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
    Labenz J; Armstrong D; Leodolter A; Baldycheva I
    Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.
    Hughes DA; Bodger K; Bytzer P; de Herdt D; Dubois D
    Pharmacoeconomics; 2005; 23(10):1031-41. PubMed ID: 16235976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.